Investigational drug · Phase 3
zipalertinib
Also called: TAS6417, CLN-081
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, Non Small Cell Lung Cancer, EGFR Exon 20 Mutation.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
7
Any phase or sponsor naming "zipalertinib"
First trial start
2019
Oct 31, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "zipalertinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
- Non Small Cell Lung Cancer
- EGFR Exon 20 Mutation
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Lung Cancer
- Adjuvant
- Post-surgical
- EGFR
- Exon 20
- Early Stage Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "zipalertinib" as an intervention, largest first.
- A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionPivotal-lookingRecruiting
Taiho Oncology, Inc.Industry
NCT07128199 · 360 participants (planned) · Start Dec 22, 2025 · Primary completion Oct 1, 2029
Drug: TAS6417; Zipalertinib Matching-placebo · For: Lung Cancer; Adjuvant; Post-surgical and 5 more
Sites: Anchorage, Alaska; Duarte, California; Irvine, California · 253 sites in all
- REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Pivotal-lookingActive, not recruiting
Taiho Oncology, Inc.Industry
NCT05973773 · 285 participants · Start Dec 18, 2023 · Primary completion May 27, 2027
Drug: TAS6417 · For: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Sites: Henderson, Nevada; Las Vegas, Nevada; Canton, Ohio · 110 sites in all
- A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerActive, not recruiting
Cullinan Therapeutics Inc.Industry
NCT04036682 · 284 participants (planned) · Start Oct 31, 2019 · Primary completion Oct 13, 2025
Drug: CLN-081 · For: Non Small Cell Lung Cancer; EGFR Exon 20 Mutation
Sites: Anaheim, California; Duarte, California; Irvine, California · 64 sites in all
- A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.Pivotal-lookingRecruiting
Taiho Oncology, Inc.Industry
NCT05967689 · 220 participants (planned) · Start Jul 31, 2023 · Primary completion Aug 31, 2028
Drug: TAS6417; CYP Cocktail and 1 more · For: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Sites: Birmingham, Alabama; Duarte, California; Boston, Massachusetts · 80 sites in all
- Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLCNot yet recruiting
Stanford UniversityAcademic, hospital or other
NCT07802834 · 42 participants (planned) · Start Nov 2026 · Primary completion Dec 2028
Drug: Zipalertinib · For: EGFR; Lung Cancer (NSCLC); Non Small Cell Lung Cancer
- Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung CancerNot yet recruiting
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT07229339 · 16 participants (planned) · Start Jun 1, 2027 · Primary completion Jun 1, 2029
Drug: Carboplatin; Pemetrexed and 1 more · For: Lung Non-Squamous Non-Small Cell Carcinoma
Sites: Los Angeles, California
Taiho Oncology, Inc.Industry
NCT07601399
Drug: Zipalertinib · For: Non-Small Cell Lung Cancer
Newest research
PubMed records naming it or its code names, newest first.
- P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.
Monaca F, Randulfe I, Heymach JV, et al. · J Clin Oncol 2026
- Phase III Trials Test First-Line Options in Advanced NSCLC.
· Cancer Discov 2026
- Perioperative treatment for resectable non-small cell lung cancer harboring EGFR exon 20 insertion mutations: a narrative review from advanced-stage evidence to whole-course precision management.
Li Z, Han Y, Zhong W, et al. · Transl Lung Cancer Res 2026
- [Retrospective Analysis of the Efficacy and Safety of Amivantamab-containing Regimens in Patients with EGFR-mutant Lung Cancer and Leptomeningeal Metastases].
Gao X, Zhong W, Liu X, et al. · Zhongguo Fei Ai Za Zhi 2026
- Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Piotrowska Z, Shao-Weng Tan D, Smit EF, et al. · J Clin Oncol 2026
- Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20-mutant NSCLC: case report.
Dabbah B, Gillis R, Salim J, et al. · Front Oncol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.